Novocure Ltd - Asset Resilience Ratio
Novocure Ltd (NVCR) has an Asset Resilience Ratio of 50.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Novocure Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Novocure Ltd's Asset Resilience Ratio has changed over time. See NVCR net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Novocure Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Novocure Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $691.38 Million | 50.79% |
| Total Liquid Assets | $691.38 Million | 50.79% |
Asset Resilience Insights
- Very High Liquidity: Novocure Ltd maintains exceptional liquid asset reserves at 50.79% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novocure Ltd Industry Peers by Asset Resilience Ratio
Compare Novocure Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Novocure Ltd (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Novocure Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 64.16% | $796.11 Million | $1.24 Billion | +5.72pp |
| 2023-12-31 | 58.44% | $669.79 Million | $1.15 Billion | -13.23pp |
| 2022-12-31 | 71.67% | $854.10 Million | $1.19 Billion | +7.71pp |
| 2021-12-31 | 63.97% | $728.90 Million | $1.14 Billion | +6.18pp |
| 2020-12-31 | 57.79% | $607.90 Million | $1.05 Billion | +26.76pp |
| 2019-12-31 | 31.03% | $148.77 Million | $479.45 Million | +0.05pp |
| 2018-12-31 | 30.98% | $105.26 Million | $339.79 Million | -8.50pp |
| 2017-12-31 | 39.47% | $104.72 Million | $265.30 Million | -3.02pp |
| 2016-12-31 | 42.49% | $119.85 Million | $282.08 Million | -6.32pp |
| 2015-12-31 | 48.81% | $150.00 Million | $307.34 Million | +10.63pp |
| 2014-12-31 | 38.17% | $45.00 Million | $117.88 Million | +37.55pp |
| 2013-12-31 | 0.62% | $1.18 Million | $188.91 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in br… Read more